 DARTMOUTH, Nova Scotia--BUSINESS WIRE--IMV Inc. Nasdaq: IMV; TSX: IMV, a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious diseases, today reports updated clinical and translational data from DeCidE1, its Phase 2 clinical study evaluating the safety and efficacy of DPX-Survivac with intermittent low-dose cyclophosphamide CPA in patients with recurrent, advanced platinum-sensitive and platinum-resistant ovar 